<DOC>
	<DOCNO>NCT00719966</DOCNO>
	<brief_summary>RATIONALE : Aromatase inhibitor therapy use treat postmenopausal woman hormone-dependent breast cancer . It yet know effect aromatase inhibitor therapy blood vessel function . PURPOSE : This clinical trial study effect aromatase inhibitor therapy blood vessel function postmenopausal woman breast cancer .</brief_summary>
	<brief_title>Effect Aromatase Inhibitor Therapy Blood Vessel Function Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect adjuvant aromatase inhibitor therapy endothelial function postmenopausal woman breast cancer . OUTLINE : This multicenter study . Patients assign 1 2 treatment group accord breast cancer hormone-receptor status ( positive v negative ) . - Group 1 ( hormone receptor-positive ) : Patients receive aromatase inhibition therapy 6 month absence unacceptable toxicity . - Group 2 ( hormone receptor-negative ) : Patients receive adjuvant treatment . Endothelial function measure group baseline follow room temperature peripheral arterial tonometry ( RT-PAT ) index use EndoPAT method .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Ductal carcinoma situ ( DCIS ) allow provide patient receive tamoxifen part treatment cancer May prior mastectomy requirement mastectomy contralateral breast No requirement axillary lymph node dissection history contralateral mastectomy and/or contralateral axillary lymph node dissection Hormone receptor status meet 1 follow criterion : Hormone receptor negative eligible aromatase inhibitor therapy ( AI ) Hormone receptor positive receiving AI PATIENT CHARACTERISTICS : Postmenopausal No known symptomatic coronary artery disease No significant comorbidities , include follow condition : Active renal hepatic disease Known uncontrolled and/or untreated peripheral arterial disease Uncontrolled and/or untreated hypertension Uncontrolled and/or untreated diabetes Uncontrolled and/or untreated hyperlipidemia PRIOR CONCURRENT THERAPY : See Disease Characteristics More 7 day since prior hormone replacement therapy hormonebased contraception More 12 month since prior concurrent tamoxifen aromatase inhibitor therapy disease More 12 month since prior concurrent chemotherapy disease No prior bilateral mastectomy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>